Aligos Therapeutics, Inc. Debt Securities, Available-for-sale
Aligos Therapeutics, Inc. (ALGS) had Debt Securities, Available-for-sale of $39.59 million as of 2024-09-30, per its 10-Q filed 2024-11-06.
Financial Statements › Balance Sheet › Assets
us-gaap:AvailableForSaleSecuritiesDebtSecurities · last filed 2025-03-10
- 2024-09-30: Debt Securities, Available-for-sale $39.59M.
- 2024-06-30: Debt Securities, Available-for-sale $49.46M.
- 2024-03-31: Debt Securities, Available-for-sale $88.59M.
- 2023-12-31: Debt Securities, Available-for-sale $0.00.
| Period end | Debt Securities, Available-for-sale |
|---|---|
| 2024-09-30 | $39.59M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $49.46M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $88.59M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-10 |
| 2023-06-30 | $10.00K 10-Q · filed 2023-08-03 |
| 2023-03-31 | $24.84M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $44.48M 10-K · filed 2023-03-09 |
| 2022-09-30 | $55.86M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $88.17M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $78.66M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $19.03M 10-K · filed 2023-03-09 |
| 2021-09-30 | $2.94M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $3.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $13.05M 10-Q · filed 2021-05-10 |
| 2020-09-30 | $23.24M 10-Q · filed 2020-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |